An Update on Prenatal Diagnosis and Treatment of Congenital Adrenal Hyperplasia

Abstract

Congenital adrenal hyperplasia causes genital ambiguity in females affected with the severe form of the disease; yet the abnormality is preventable with prenatal dexamethasone treatment that must be given to the mother before the ninth week of gestation. In the period from 1978 to March 2011 we have made prenatal diagnosis in 719 pregnancies. Our results indicate that the average Prader score of those fetuses treated with dexamethasone was 1.7, which is much lower than the average Prader score of 3.73 in those not treated. While our data demonstrate no significant abnormalities in the long-range medical and cognitive outcomes in patients prenatally treated with dexamethasone, the current protocol involves invasive procedures such as chorionic villus sampling or amniocentesis, and all fetuses are treated unnecessarily for several weeks before the sex and the affection status of the fetus is known. We are collaborating with Dr. Dennis Lo in Hong Kong to develop a noninvasive protocol, whereby at the sixth to seventh week of gestation we can determine the sex and the affection status of the fetus by harvesting fetal DNA from the maternal plasma. The method will eliminate invasive procedures and unnecessary prenatal treatment and bring noninvasive prenatal diagnosis to underdeveloped areas where amniocentesis and chorionic villus sampling are not available.

Keywords

congenital adrenal hyperplasia - prenatal treatment - genital ambiguity - noninvasive prenatal diagnosis - dexamethasone

• References

• 1 Hormonal and Genetic Basis of Sexual Differentiation Disorders and Hot Topic in Endocrinology. Proceedings of the 2^nd World Conference. New MI, Simpson JL (eds). Springer 2011
• 2 Hirvikoski T, Nordenström A, Lindholm T , et al. Cognitive functions in children at risk for congenital adrenal hyperplasia treated prenatally with dexamethasone. J Clin Endocrinol Metab 2007; 92 (2) 542-548
• 3 Hirvikoski T, Nordenström A, Lindholm T, Lindblad F, Ritzén EM, Lajic S. Long-term follow-up of prenatally treated children at risk for congenital adrenal hyperplasia: does dexamethasone cause behavioural problems?. Eur J Endocrinol 2008; 159 (3) 309-316
• 4 Chan KC, Lo YM. Circulating nucleic acids as a tumor marker. Histol Histopathol 2002; 17 (3) 937-943
• 5 Bischoff FZ, Nguyen DD, Marquéz-Do D, Moise Jr KJ, Simpson JL, Elias S. Noninvasive determination of fetal RhD status using fetal DNA in maternal serum and PCR. J Soc Gynecol Investig 1999; 6 (2) 64-69
• 6 Lo YM, Lau TK, Zhang J , et al. Increased fetal DNA concentrations in the plasma of pregnant women carrying fetuses with trisomy 21. Clin Chem 1999; 45 (10) 1747-1751
• 7 Farina A, LeShane ES, Lambert-Messerlian GM , et al. Evaluation of cell-free fetal DNA as a second-trimester maternal serum marker of Down syndrome pregnancy. Clin Chem 2003; 49 (2) 239-242
• 8 Johnson KL, Dukes KA, Vidaver J , et al. Interlaboratory comparison of fetal male DNA detection from common maternal plasma samples by real-time PCR. Clin Chem 2004; 50 (3) 516-521
• 9 Wright CF, Burton H. The use of cell-free fetal nucleic acids in maternal blood for non-invasive prenatal diagnosis. Hum Reprod Update 2009; 15 (1) 139-151
• 10 Crouch NS, Minto CL, Laio LM, Woodhouse CRJ, Creighton SM. Genital sensation after feminizing genitoplasty for congenital adrenal hyperplasia: a pilot study. BJU Int 2004; 93 (1) 135-138
• 11 Crouch NS, Liao LM, Woodhouse CR, Conway GS, Creighton SM. Sexual function and genital sensitivity following feminizing genitoplasty for congenital adrenal hyperplasia. J Urol 2008; 179 (2) 634-638